234 related articles for article (PubMed ID: 38339383)
1. Cholangiocarcinoma Insights: Established Foundations and Cutting-Edge Innovations from Dr. James Cleary's Pioneering Research.
Cortiana V; Chorya H; Joshi M; Kannan S; Mahendru D; Vallabhaneni H; Coloma HS; Leyfman Y; Park CH
Cancers (Basel); 2024 Feb; 16(3):. PubMed ID: 38339383
[TBL] [Abstract][Full Text] [Related]
2. Emerging molecular therapeutic targets for cholangiocarcinoma.
Ilyas SI; Gores GJ
J Hepatol; 2017 Sep; 67(3):632-644. PubMed ID: 28389139
[TBL] [Abstract][Full Text] [Related]
3. Cholangiocarcinoma.
Brindley PJ; Bachini M; Ilyas SI; Khan SA; Loukas A; Sirica AE; Teh BT; Wongkham S; Gores GJ
Nat Rev Dis Primers; 2021 Sep; 7(1):65. PubMed ID: 34504109
[TBL] [Abstract][Full Text] [Related]
4. Developments in FGFR and IDH inhibitors for cholangiocarcinoma therapy.
Brown ZJ; Ruff SM; Pawlik TM
Expert Rev Anticancer Ther; 2023 Mar; 23(3):257-264. PubMed ID: 36744395
[TBL] [Abstract][Full Text] [Related]
5. The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets.
Chong DQ; Zhu AX
Oncotarget; 2016 Jul; 7(29):46750-46767. PubMed ID: 27102149
[TBL] [Abstract][Full Text] [Related]
6. Lack of Targetable FGFR2 Fusions in Endemic Fluke-Associated Cholangiocarcinoma.
Kongpetch S; Jusakul A; Lim JQ; Ng CCY; Chan JY; Rajasegaran V; Lim TH; Lim KH; Choo SP; Dima S; Popescu I; Duda DG; Kukongviriyapan V; Khuntikeo N; Pairojkul C; Rozen SG; Tan P; Teh BT
JCO Glob Oncol; 2020 Apr; 6():628-638. PubMed ID: 32315234
[TBL] [Abstract][Full Text] [Related]
7. FGFR Inhibitors: Clinical Activity and Development in the Treatment of Cholangiocarcinoma.
King G; Javle M
Curr Oncol Rep; 2021 Jul; 23(9):108. PubMed ID: 34269915
[TBL] [Abstract][Full Text] [Related]
8. Cholangiocarcinoma: Recent Advances in Molecular Pathobiology and Therapeutic Approaches.
Khosla D; Misra S; Chu PL; Guan P; Nada R; Gupta R; Kaewnarin K; Ko TK; Heng HL; Srinivasalu VK; Kapoor R; Singh D; Klanrit P; Sampattavanich S; Tan J; Kongpetch S; Jusakul A; Teh BT; Chan JY; Hong JH
Cancers (Basel); 2024 Feb; 16(4):. PubMed ID: 38398194
[TBL] [Abstract][Full Text] [Related]
9. Targeting FGFR in intrahepatic cholangiocarcinoma [iCCA]: leading the way for precision medicine in biliary tract cancer [BTC]?
Aitcheson G; Mahipal A; John BV
Expert Opin Investig Drugs; 2021 Apr; 30(4):463-477. PubMed ID: 33678096
[No Abstract] [Full Text] [Related]
10. Cell of origin in biliary tract cancers and clinical implications.
Moeini A; Haber PK; Sia D
JHEP Rep; 2021 Apr; 3(2):100226. PubMed ID: 33665585
[TBL] [Abstract][Full Text] [Related]
11. The rise of the FGFR inhibitor in advanced biliary cancer: the next cover of time magazine?
Ilyas SI; Borad MJ
J Gastrointest Oncol; 2016 Oct; 7(5):789-796. PubMed ID: 27747092
[TBL] [Abstract][Full Text] [Related]
12. Practical considerations in screening for genetic alterations in cholangiocarcinoma.
Bekaii-Saab TS; Bridgewater J; Normanno N
Ann Oncol; 2021 Sep; 32(9):1111-1126. PubMed ID: 33932504
[TBL] [Abstract][Full Text] [Related]
13. Infigratinib for the Treatment of Metastatic or Locally Advanced Cholangiocarcinoma With Known FGFR2 Gene Fusions or Rearrangements.
White K; Anwar AI; Jin K; Bollich V; Kelkar RA; Talbot NC; Klapper RJ; Ahmadzadeh S; Viswanath O; Varrassi G; Shekoohi S; Kaye AD
Cureus; 2023 Oct; 15(10):e46792. PubMed ID: 37954763
[TBL] [Abstract][Full Text] [Related]
14. Precision Medicine in Cholangiocarcinoma: Past, Present, and Future.
Cheng CY; Chen CP; Wu CE
Life (Basel); 2022 Jun; 12(6):. PubMed ID: 35743860
[TBL] [Abstract][Full Text] [Related]
15. IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver?
Rizzo A; Ricci AD; Brandi G
Cancer Treat Res Commun; 2021; 27():100356. PubMed ID: 33799004
[TBL] [Abstract][Full Text] [Related]
16. Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma.
Jusakul A; Cutcutache I; Yong CH; Lim JQ; Huang MN; Padmanabhan N; Nellore V; Kongpetch S; Ng AWT; Ng LM; Choo SP; Myint SS; Thanan R; Nagarajan S; Lim WK; Ng CCY; Boot A; Liu M; Ong CK; Rajasegaran V; Lie S; Lim AST; Lim TH; Tan J; Loh JL; McPherson JR; Khuntikeo N; Bhudhisawasdi V; Yongvanit P; Wongkham S; Totoki Y; Nakamura H; Arai Y; Yamasaki S; Chow PK; Chung AYF; Ooi LLPJ; Lim KH; Dima S; Duda DG; Popescu I; Broet P; Hsieh SY; Yu MC; Scarpa A; Lai J; Luo DX; Carvalho AL; Vettore AL; Rhee H; Park YN; Alexandrov LB; Gordân R; Rozen SG; Shibata T; Pairojkul C; Teh BT; Tan P
Cancer Discov; 2017 Oct; 7(10):1116-1135. PubMed ID: 28667006
[TBL] [Abstract][Full Text] [Related]
17. Fibroblast growth factor receptor (FGFR) inhibitors in cholangiocarcinoma: current status, insight on resistance mechanisms and toxicity management.
Chakrabarti S; Finnes HD; Mahipal A
Expert Opin Drug Metab Toxicol; 2022 Jan; 18(1):85-98. PubMed ID: 35129006
[TBL] [Abstract][Full Text] [Related]
18. Future directions in the treatment of cholangiocarcinoma.
Zhu AX
Best Pract Res Clin Gastroenterol; 2015 Apr; 29(2):355-61. PubMed ID: 25966434
[TBL] [Abstract][Full Text] [Related]
19. FGFR2 Inhibition in Cholangiocarcinoma.
Vogel A; Segatto O; Stenzinger A; Saborowski A
Annu Rev Med; 2023 Jan; 74():293-306. PubMed ID: 36170665
[TBL] [Abstract][Full Text] [Related]
20. Validation and Characterization of FGFR2 Rearrangements in Cholangiocarcinoma with Comprehensive Genomic Profiling.
Silverman IM; Li M; Murugesan K; Krook MA; Javle MM; Kelley RK; Borad MJ; Roychowdhury S; Meng W; Yilmazel B; Milbury C; Shewale S; Feliz L; Burn TC; Albacker LA
J Mol Diagn; 2022 Apr; 24(4):351-364. PubMed ID: 35176488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
